The Trump administration is advancing a major policy shift toward psychedelic-based mental health treatments. On April 18, President Donald Trump signed an executive order directing the FDA to accelerate the development and approval process for psychedelic drugs, including ibogaine compounds, psilocybin, and methylone. Just days later, on April 24, the FDA announced it was fast-tracking review for three companies studying these substances as treatments for major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.
Federal Drivers and Clinical Evidence
The executive order cites a 37% increase in suicide rates from 2000 to 2018 and a veteran suicide rate more than double that of the non-veteran adult population. It mandates that the FDA provide National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designation and allocates at least $50 million from existing funds to support state governments developing psychedelic programs.
A systematic review examining six studies involving 319 participants found that psilocybin significantly reduced depressive symptoms with few side effects, showing advantages over commonly prescribed SSRIs, which carry more risk and cause more adverse effects. However, researchers noted that just a few clinical trials have been completed, and no Phase 3 trials for methylone have been finalized to confirm safety and efficacy.
Right-to-Try Access and Regulatory Pathways
The order directs the FDA and Drug Enforcement Administration to create pathways for eligible patients to access these drugs under the Right to Try Act, including necessary Schedule I handling authorizations for treating physicians. Secretary of Health and Human Services Robert F. Kennedy Jr. amplified the message at a Senate hearing on April 22, stating the administration is accelerating research and approval for psychedelic therapies to confront the nation’s mental health crisis, especially for veterans.
The FDA also approved a Phase 1 clinical trial of noribogaine hydrochloride—a safer derivative of ibogaine—for alcohol use disorder, though officials emphasized this does not mean the FDA has found ibogaine safe or effective for any condition, noting its well-documented heart health risks. The current executive order specifically requires the Attorney General to initiate review of any Schedule I substance that successfully completes Phase 3 clinical trials, so rescheduling can proceed quickly for FDA-approved products.
Implications for American Mental Health
For the 14 million American adults with serious mental illness and the 8 million on prescription medications for these conditions, this federal action opens new treatment possibilities. All these substances require administration under medical supervision with psychological support, which was included as an integral part of treatment in every psilocybin study reviewed.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.naturalnews.com/2026-04-27-fda-fast-tracks-psychedelic-drugs-for-depression-and-ptsd-treatment.html